FitzGerald D J, Bjorn M J, Ferris R J, Winkelhake J L, Frankel A E, Hamilton T C, Ozols R F, Willingham M C, Pastan I
Cancer Res. 1987 Mar 1;47(5):1407-10.
An immunotoxin composed of an antibody to the human transferrin receptor (454A12) and ricin A chain (RTA) was shown to inhibit the growth of NIH:OVCAR-3 tumors in a nude mouse model of human ovarian cancer. Inhibition of tumor growth by 454A12-RTA was related to the dose administered. The antitumor activity of the immunotoxin was blocked by coinjection of excess antibody with immunotoxin. An immunotoxin made using 454A12 and recombinant ricin A chain (rRTA) had an activity similar to that made with native RTA. The administration of 10 micrograms or greater of the immunotoxin 454A12-RTA/rRTA had significant antitumor activity. The injection of 30 micrograms of an irrelevant immunotoxin, MOPC21-RTA, or 30 to 500 micrograms of the 454A12 antibody had no antitumor activity.
一种由抗人转铁蛋白受体抗体(454A12)和蓖麻毒素A链(RTA)组成的免疫毒素,在人卵巢癌裸鼠模型中显示出可抑制NIH:OVCAR-3肿瘤的生长。454A12-RTA对肿瘤生长的抑制作用与给药剂量相关。通过将过量抗体与免疫毒素共同注射,可阻断免疫毒素的抗肿瘤活性。使用454A12和重组蓖麻毒素A链(rRTA)制备的免疫毒素,其活性与使用天然RTA制备的免疫毒素相似。给予10微克或更多的免疫毒素454A12-RTA/rRTA具有显著的抗肿瘤活性。注射30微克无关免疫毒素MOPC21-RTA或30至500微克454A12抗体均无抗肿瘤活性。